In the latest trading session, Hologic (HOLX - Free Report) closed at $75.89, marking a +0.15% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.61%. Meanwhile, the Dow lost 0.42%, and the Nasdaq, a tech-heavy index, added 0.17%.
Prior to today's trading, shares of the medical device maker had gained 1.57% over the past month. This has lagged the Medical sector's gain of 5.48% and outpaced the S&P 500's gain of 0.89% in that time.
Investors will be hoping for strength from Hologic as it approaches its next earnings release. The company is expected to report EPS of $0.87, down 59.91% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $962.24 million, down 34.59% from the prior-year quarter.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $3.46 per share and revenue of $3.81 billion. These results would represent year-over-year changes of -42.52% and -21.56%, respectively.
Investors should also note any recent changes to analyst estimates for Hologic. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Hologic is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Hologic's current valuation metrics, including its Forward P/E ratio of 21.88. Its industry sports an average Forward P/E of 29.41, so we one might conclude that Hologic is trading at a discount comparatively.
We can also see that HOLX currently has a PEG ratio of 1.44. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. HOLX's industry had an average PEG ratio of 2.35 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HOLX in the coming trading sessions, be sure to utilize Zacks.com.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
In the latest trading session, Hologic (HOLX - Free Report) closed at $75.89, marking a +0.15% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.61%. Meanwhile, the Dow lost 0.42%, and the Nasdaq, a tech-heavy index, added 0.17%.
Prior to today's trading, shares of the medical device maker had gained 1.57% over the past month. This has lagged the Medical sector's gain of 5.48% and outpaced the S&P 500's gain of 0.89% in that time.
Investors will be hoping for strength from Hologic as it approaches its next earnings release. The company is expected to report EPS of $0.87, down 59.91% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $962.24 million, down 34.59% from the prior-year quarter.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $3.46 per share and revenue of $3.81 billion. These results would represent year-over-year changes of -42.52% and -21.56%, respectively.
Investors should also note any recent changes to analyst estimates for Hologic. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Hologic is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Hologic's current valuation metrics, including its Forward P/E ratio of 21.88. Its industry sports an average Forward P/E of 29.41, so we one might conclude that Hologic is trading at a discount comparatively.
We can also see that HOLX currently has a PEG ratio of 1.44. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. HOLX's industry had an average PEG ratio of 2.35 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HOLX in the coming trading sessions, be sure to utilize Zacks.com.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Get the latest research report on HOLX - FREE